Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 84
3 119
2 31
1 18
Curative setting
A 34
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 43
Genitourinary Cancers 49
Gynaecological Malignancies 28
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 20
Thoracic Malignancies 64
Curative setting
Breast Cancer 6
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 2
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
Thoracic Malignancies 2

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
Trastuzumab - Chemotherapy Adjuvant or neo-adjuvant HER2 positive tumours Breast Cancer Breast Cancer HER2+ Early
A
Epirubicin, 5FU, Cisplatin - Surgery Peri-operative Gastrointestinal Cancers Gastric or gastro-oesophageal junction adenocarcinoma - Early
A
5-FU, Cisplatin - Surgery Peri-operative Gastrointestinal Cancers Gastric or gastro-oesophageal junction adenocarcinoma - Early
A
Ipilimumab - Placebo Adjuvant stage III melanoma Skin Cancers Melanoma - Adjuvant
A
Ipilimumab Dacarbazine Dacarbazine + placebo 1st line treatment Skin Cancers Melanoma - Metastatic
4
Dinutuximab Cis retinoic acid+GMCSF+IL2 Cis retinoic acid <32 years old with high-risk neuroblastoma after remission and stem cell transplatation Central Nervous System Malignancies Neuro-oncology cancer - Neuroblastoma - Early
A
FLOT (docetaxel, oxaliplatin, fluorouracil and leucovorin) - Fluorouracil or capecitabine plus cisplatin and epirubicin Resectable gastric or gastro-oesophageal junction adenocarcinoma with clinical stage cT2 or higher, nodal positive (cN+) disease or both Gastrointestinal Cancers Gastric or gastro-oesophageal junction adenocarcinoma - Early
A
Gemcitabine Capecitabine Gemcitabine Resected pancreatic ductal adenocarcinoma Gastrointestinal Cancers Pancreatic cancer - Early
A
mFOLFIRINOX - Gemcitabine Resected pancreatic ductal adenocarcinoma Gastrointestinal Cancers Pancreatic cancer - Early
A
Pertuzumab Standard adjuvant chemotherapy + 1 year of treatment with trastuzumab Placebo + standard adjuvant chemotherapy + 1 year of treatment with trastuzumab Adjuvant early HER2+ Breast Cancer Breast Cancer HER2+ Early
A

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.